Phase 4 N=60 Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
Psoriasis
Primary: Investigator's Global Assessment (IGA) — 15 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
Refractory Solid Tumors in Children
Primary: Dose Limiting Toxicity — 2 participants
N/A N=372 Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution
Refractive Error · Myopia · Hyperopia
Primary: Likert Scale Questionnaire Item: "I Can Comfortably Wear my Lenses" — 4.2; 4.4 units on a scale
N/A N=86 Bifocal Soft Contact Lenses and Their Effect on Myopia Progression in Children and Adolescents.
Myopia · Esophoria · Fixation Disparity
Primary: Changes in Cycloplegic Autorefraction in One Year. — -0.22; -0.78 Diopters
Phase 1 N=23 Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Healthy
Primary: Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss) — 5850; 5680 nmol*h/L
Phase 1 N=15 Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) — 2; 1 Participants
Phase 4 N=376 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)
Phase 2 N=22 Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
Recurrent Small Cell Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Overall Response Rate (Phase II) — 0; 0; 0; 0 participants
N/A N=210 Homeopathic Ear Drops for Otitis Media Study
Otitis Media
Primary: Severity of Symptoms of Otitis Media — 2.0; 2.0 units on a scale
N/A N=181 Determining the Depth of Endotracheal Tube Insertion
Endotracheal Intubation · Individualized Depth of Endotracheal Intubation
Primary: Comparison of Airway Length Between Male and Female — 0.9; 1.1; 9.1; 8.3 Centimeters
N/A N=573 Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
Epilepsies, Partial
Primary: Clinical Global Impression of Change (CGI-C) at Month 6 — 160; 179; 66; 72 participants
N/A N=46 A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
Virus Diseases · HIV
Primary: Number of Patients With Suppressed Viral Load(<75 Copies/ml)in Raltegravir 400 mg Bid vs. NRTI Backbone, Each in Combination of Boosted PI Regimen — 18; 18 participants…
Phase 2 N=328 Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Cystinosis
Primary: Number of Participants With Serious and Non-Serious Adverse Events — 257 participants
Phase 4 N=95 A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events — 8.4; 0; 38.9; 45.3 percentage of participants
Phase 4 N=219 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
Osteoporosis, Postmenopausal
Primary: Base Study: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 — 3.54; 1.59 Percent change — p=<0.001